sorafenib has been researched along with jrf 12 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (jrf 12) | Trials (jrf 12) | Recent Studies (post-2010) (jrf 12) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 34 | 0 | 33 |
| Protein | Taxonomy | sorafenib (IC50) | jrf 12 (IC50) |
|---|---|---|---|
| Valosin-containing protein | Homo sapiens (human) | 1.95 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arma, D; Balabaud, C; Bexiga, MG; Bioulac-Sage, P; Blanc, JF; Castain, C; Chevet, E; Higa, A; Le Bail, B; Marza, E; Rosenbaum, J; Simpson, JC; Taouji, S; Yi, P | 1 |
1 other study(ies) available for sorafenib and jrf 12
| Article | Year |
|---|---|
Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Secretory Pathway; Sorafenib | 2012 |